CLOSED STUDIES / Ovarian Cancer


GEICO 0901 / AGO-OVAR 16


Title

Phase III study to evaluate the efficacy and safety of pazopanib as monotherapy versus placebo amongst women with epithelial ovarian, fallopian tube or primary peritoneal cancer who have not progressed after first-line chemotherapy.


EudraCT

2008-004672-50


GEICO Coordinator

Dr. José María del Campo


Patients Recruited

80 patients


Inclusion Closing Date

July of 2010


Current State

Following